Boehringer Ingelheim acquires Amgen biotech site

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Boehringer Ingelheim acquires Amgen biotech site

Biosimilares/Novedades | Posted 08/04/2011 0 Post your comment

Boehringer Ingelheim, one of the world’s leading companies for contract development and manufacturing of biopharmaceuticals, announced on 25 March 2011 that it had formally acquired Amgen’s biopharmaceutical development and manufacturing facility in Fremont, California, USA.

The agreement to acquire the facility, which was signed back in January 2011, involves leasing buildings, acquiring physical equipment and assuming manufacturing processes done at the Fremont site.

'Presence in Fremont, CA, [USA,] aligns with our growth strategy in several ways’, said Mr Simon Sturge, Corporate Senior Vice President Biopharmaceuticals, Boehringer Ingelheim, adding that ‘the technological expertise present at Fremont will complement our goal to further increase Boehringer Ingelheim’s world leading position in the process development and manufacture of Biopharmaceuticals’.

Boehringer Ingelheim has been a contract manufacturer for Amgen for ten years and the company states that they will continue to support Amgen’s delivery of safe and effective medicines to patients around the world.

Boehringer Ingelheim provides all types of services from mammalian cell line or microbial strain development to final drug production and global market supply. The company has brought 18 molecules to market and has years of experience in biotech molecules such as monoclonal antibodies, recombinant proteins, interferons, enzymes, fusion molecules, novel scaffold proteins and plasmid DNA. It is therefore perfectly placed to enter the biosimilars race. Is this its intention with the acquisition of the state-of-the art Fremont facility? Only time will tell.

Source: Amgen, Boehringer Ingelheim